Alphavirus vectors for paramyxovirus vaccines
a technology of paramyxovirus and betavirus, which is applied in the field of betavirus vectors for paramyxovirus vaccines, can solve the problems of imbalance in cell-mediated responses, inability to fully adapt to large-scale vaccine production, and inability to provide vaccines, etc., and achieves low dose, less time, and high anti-f igg antibody
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
[0062] EXAMPLE 1
[0063] This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in FIGS. 1A to 1B.
[0064] Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The .beta.-globin intron II was exised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:
2 (Seq ID no:7) TCGACATGGCGGATGTGTGACATACACGACGCCAAMGATTTTG-TTCCAGC TCCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCA-A AGTGCATGTTGATATTGAGGCTGACAGCCCATTCATCAAAGTCTTTGCAG AAGGCATTTCCGTCGTTCGAGGTTCGAGTCATTGCAGGTCACACCAAATG ACCATGCAAATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAG CAGGAGACTGACAAAGACACACTCATCTTGGAT
[0065] generated from pSFVI with primers SAL-SFV having the nucleotide The resulting plasmid pMP38 was then restricted with EcoRV-TCCACCTCCAAGATATCC-AAGATGAGTGTG...
example 2
[0067] EXAMPLE 2
[0068] This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in FIG. 2.
[0069] Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The .beta.-globin Intron II was exised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:
3 (SEQ ID no: 7) TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTT-TGTTCCAG CTCCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGC-CA AAGTGCATGTTGATATTGAGGCTGACAGCCCATTCATCAAGTCTTTGCAG AAGGCATTTCCGTCGTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGA CCATGCAAATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGC AGGAGACTGACAAAGACACACTCATCTTGGAT
[0070] generated from pSFVI with primers SAL-SFV having the nucleotide sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 5) and ECO-SFV having the nucleotide sequence 5'- TCCACCTCCAAG-ATATCCAAGATGAGTGTG (SEQ ID no: 6). The re...
example 3
[0072] EXAMPLE 3
[0073] This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained. BALB / C mice were immunized with plasmid pMP44 by the intramuscular (i.m.) route. The anterior tibialts muscles of six BALB / C mice were bilaterally injected with 2.times.100 .mu.g of plasmid pMP44 This amount is equivalent to approximately 94 .mu.g of a conventional vector, based on copy number. These mice were boosted in an identical manner 4 weeks later. The control group was immunized with 2 .times.25 .mu.g of SFV-RSV F RNA as described in my aforementioned U.S. application Ser. No. 08 / 923,558, except that the muscles were not pre-treated with cardiotoxin. The immunization protocol is set forth in the following Table I:
4TABLE 1 Immunization protocol Route of Route of Group Prime Inoculation Boost Inoculation 1 SFV-RSVF RNA.sup.1 Intramuscular SFV-RSVF RNA.sup.1 Intramuscular 2 pMP44 DNA.sup.2 Intramuscular pMP44DNA.sup.2 Intramuscular
[0074] Mice were inoculate...
PUM
| Property | Measurement | Unit |
|---|---|---|
| temperatures | aaaaa | aaaaa |
| length RSV | aaaaa | aaaaa |
| resistance | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More